Pfizer Inc (NYSE: PFE) closed at $25.48, rising 6.83%. Volume soared to over 153 million shares, nearly 3.5 times its three-month average of 43.3 million.
Indexes advanced modestly, led by healthcare and industrial strength. The S&P 500 (SNPINDEX: ^GSPC) gained 0.41% to 6,688.46, and the Nasdaq Composite (NASDAQINDEX: ^IXIC) ticked up 0.30% to 22,660.01, as health and industrial sectors led gains.
Among large pharma peers, Johnson & Johnson (NYSE: JNJ) ended at $185.42, up 2.09%, while Eli Lilly and Co (NYSE: LLY) finished at $763.00, up 5.02%. Both stocks showed strength on sector momentum tied to the policy move.
Pfizer’s rally followed news of a high-profile agreement with the Trump administration. The company will reduce many drug prices, particularly in Medicaid, by matching the lowest prices abroad and launching new medicines at parity. In return, Pfizer secured a three-year exemption from planned import tariffs and committed to invest about $70 billion in U.S. manufacturing. The deal also ties Pfizer to TrumpRx, a newly announced direct-to-consumer drug sales platform. While the near-term boost in sentiment was clear, the long-term financial impact will depend on how price concessions balance against expanded production and potential volume growth.
Market data sourced from Google Finance and Yahoo! Finance on Tuesday, Sept. 30, 2025.
Should you invest $1,000 in Pfizer right now?
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $650,607!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,114,716!*
Now, it’s worth noting Stock Advisor’s total average return is 1,068% — a market-crushing outperformance compared to 190% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of September 29, 2025
Daily Stock News has no position in any of the stocks mentioned. This article was generated with GPT-5, OpenAI’s large-scale language generation model and has been reviewed by The Motley Fool’s AI quality control systems. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
#Stock #Market #Today #Pfizer #Rallies #Trump #Drug #Pricing #Deal #U.S #Investment #Pledge